Codexis Adds Life Sciences Industry Veteran David V. Smith to Its Board of Directors

David V. Smith

On Thursday, March 03, 2016 Codexis announced the appointment of David V. Smith to its Board of Directors, increasing the size of the Board to nine Directors. Mr. Smith brings to Codexis more than 30 years of financial and operational management experience that includes senior executive positions in multibillion-dollar life sciences companies.

Continue reading

Origins of Stereoselectivity in Evolved Ketoreductases (PNAS)

Overlay of the crystal structuresThis week, Codexis was proud to announce the publication of a recently collaborated paper in the Proceedings of the National Academy of Sciences of the United States of America (PNAS). Read full paper here

The paper, titled “Origins of Stereoselectivity in Evolved Ketoreductases”, was a collaboration between scientists at Codexis and UCLA. The research looks at a combined theoretical-experimental effort to rationalize the origin of stereoselectivity in evolved ketoreductases. Understanding how mutations impact this stereoselectivity can be important in the development of new biocatalysts.

Continue reading

Biological Manufacturing in the Food and Beverage Industry

vanilla codexis

Vanilla, a very popular flavoring worldwide. Source:

In the food and beverage industry it is vital that manufacturers get the right combination of flavorings, fragrances, sweeteners and colorings to ensure food is as appealing as possible. Fragrance alone can be enough to have people salivating with excitement or recoiling in disgust before they have even tried the product. Different flavors, sweeteners, and fragrances are derived largely from natural sources, chemical synthesis and fermentation1. Continue reading

Codexis Announces CodeEvolver Technology Transfer and License Agreement With Merck

Codexis & Merck License Agreement

The following is a press release issued by Codexis, Inc. on Monday, August 3rd, 2015:

Codexis to Receive $5 Million in Upfront Payment

Codexis to Hold Conference Call on Tuesday, August 4, 2015 at 11:00 a.m. Eastern Time

Continue reading

“Evolving BVMO’s” – Codexis Feature in Chemistry Today

Oxidation reactions can be a challenge for the chemicals industry with concerns about safety, selectivity, side reactions and over oxidations. Codexis is using biocatalysis to overcome these challenges and has recently evolved a novel Baeyer-Villiger monooxygenase (BVMO) enzyme. The enzyme has been optimized for high performance, commercial-scale manufacture of esomeprazole (Nexium®, for the treatment of gastro-esophageal reflux)

Continue reading

Celebrating Mandy Vink’s 10 Years of Service

Mandy Photo

Last week we had the privilege of honoring Mandy Vink, Director of Business Development at Codexis, for her 10 successful years of service at Codexis! With her hard work and true dedication to the company, she has proven herself to be a true asset to the team. Her colleagues recognized her inspiring passion for the field, and her innate ability to build relationships with anyone; both coworkers and customers alike! We are delighted to have Mandy a part of our team and toast to 10 more years ahead!

Continue reading

Harnessing the power of P450 enzymes for large-scale manufacturing

Cytochrome P450 monooxygenases (P450s) have been the subject of extensive research for decades. These enzymes are involved in numerous metabolic and synthetic processes, and are best known for their role in clearing toxic chemicals including pharmaceuticals. This in turn makes them highly significant for the pharmaceutical industry, not only for their potential to influence drug interactions and drug metabolism, but also as therapeutic targets. P450s continue to be a valuable research tool at the small scale due to their ability to catalyze the incorporation of an oxygen atom into unactivated C-H bonds. However, the incorporation of a P450 enzyme by process chemists has come up against hurdles that to date have prevented these powerful enzymes from being used at manufacturing scale. Here we consider some of those limitations along with recent developments in biocatalysis that may overcome these challenges, allowing pharma and other manufacturing industries to gain from the significant cost advantages of incorporating P450-regulated chemistries into their processes.

Continue reading